Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.

Hunter MJ, Zhao H, Tuschong LM, Bauer TR Jr, Burkholder TH, Persons DA, Hickstein DD.

Hum Gene Ther. 2011 Jun;22(6):689-96. doi: 10.1089/hum.2010.130. Epub 2011 Apr 11.

2.

Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.

Hunter MJ, Tuschong LM, Fowler CJ, Bauer TR Jr, Burkholder TH, Hickstein DD.

Mol Ther. 2011 Jan;19(1):113-21. doi: 10.1038/mt.2010.203. Epub 2010 Sep 21.

3.

Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.

Nelson EJ, Tuschong LM, Hunter MJ, Bauer TR Jr, Burkholder TH, Hickstein DD.

Gene Ther. 2010 May;17(5):672-7. doi: 10.1038/gt.2010.7. Epub 2010 Feb 18.

4.

Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.

Bauer TR Jr, Tuschong LM, Calvo KR, Shive HR, Burkholder TH, Karlsson EK, West RR, Russell DW, Hickstein DD.

Mol Ther. 2013 May;21(5):964-72. doi: 10.1038/mt.2013.34. Epub 2013 Mar 26.

5.

Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.

Bauer TR Jr, Olson EM, Huo Y, Tuschong LM, Allen JM, Li Y, Burkholder TH, Russell DW.

Gene Ther. 2011 Jun;18(6):553-9. doi: 10.1038/gt.2010.169. Epub 2011 Jan 13.

6.

Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.

Bauer TR Jr, Hai M, Tuschong LM, Burkholder TH, Gu YC, Sokolic RA, Ferguson C, Dunbar CE, Hickstein DD.

Blood. 2006 Nov 15;108(10):3313-20. Epub 2006 Jul 25.

7.

Conversion of the severe to the moderate disease phenotype with donor leukocyte microchimerism in canine leukocyte adhesion deficiency.

Gu YC, Bauer TR, Sokolic RA, Hai M, Tuschong LM, Burkholder T, Bacher J, Starost MF, Hickstein DD.

Bone Marrow Transplant. 2006 Mar;37(6):607-14.

PMID:
16444276
8.

Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.

Bauer TR Jr, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM, Adler RL, Burkholder TH, Gu YC, Russell DW, Hickstein DD.

Nat Med. 2008 Jan;14(1):93-7. Epub 2007 Dec 23.

9.

Very low levels of donor CD18+ neutrophils following allogeneic hematopoietic stem cell transplantation reverse the disease phenotype in canine leukocyte adhesion deficiency.

Bauer TR Jr, Creevy KE, Gu YC, Tuschong LM, Donahue RE, Metzger ME, Embree LJ, Burkholder T, Bacher JD, Romines C, Thomas ML 3rd, Colenda L, Hickstein DD.

Blood. 2004 May 1;103(9):3582-9. Epub 2004 Jan 8.

10.

A missense mutation in the beta-2 integrin gene (ITGB2) causes canine leukocyte adhesion deficiency.

Kijas JM, Bauer TR Jr, Gäfvert S, Marklund S, Trowald-Wigh G, Johannisson A, Hedhammar A, Binns M, Juneja RK, Hickstein DD, Andersson L.

Genomics. 1999 Oct 1;61(1):101-7.

PMID:
10512685
11.

Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type I.

Leon-Rico D, Aldea M, Sanchez-Baltasar R, Mesa-Nuñez C, Record J, Burns SO, Santilli G, Thrasher AJ, Bueren JA, Almarza E.

Hum Gene Ther. 2016 Sep;27(9):668-78. doi: 10.1089/hum.2016.016. Epub 2016 May 5.

12.

Canine leukocyte adhesion deficiency colony for investigation of novel hematopoietic therapies.

Creevy KE, Bauer TR Jr, Tuschong LM, Embree LJ, Colenda L, Cogan K, Starost MF, Haskins ME, Hickstein DD.

Vet Immunol Immunopathol. 2003 Jul 15;94(1-2):11-22.

PMID:
12842608
13.

Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.

Sokolic RA, Bauer TR, Gu YC, Hai M, Tuschong LM, Burkholder T, Colenda L, Bacher J, Starost MF, Hickstein DD.

Biol Blood Marrow Transplant. 2005 Oct;11(10):755-63.

15.

Mixed chimeric hematopoietic stem cell transplant reverses the disease phenotype in canine leukocyte adhesion deficiency.

Creevy KE, Bauer TR Jr, Tuschong LM, Embree LJ, Silverstone AM, Bacher JD, Romines C, Garnier J, Thomas ML 3rd, Colenda L, Hickstein DD.

Vet Immunol Immunopathol. 2003 Oct 15;95(3-4):113-21.

PMID:
12963272
16.

Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy.

Hai M, Adler RL, Bauer TR Jr, Tuschong LM, Gu YC, Wu X, Hickstein DD.

Gene Ther. 2008 Jul;15(14):1067-71. doi: 10.1038/gt.2008.52. Epub 2008 Mar 27.

PMID:
18369320
17.

Nonmyeloablative hematopoietic stem cell transplantation corrects the disease phenotype in the canine model of leukocyte adhesion deficiency.

Bauer TR Jr, Gu YC, Tuschong LM, Burkholder T, Bacher JD, Starost MF, Donahue RE, Sokolic RA, Hickstein DD.

Exp Hematol. 2005 Jun;33(6):706-12.

PMID:
15911095
18.

Detection of the causal mutation for canine leukocyte adhesion deficiency (CLAD) using pyrosequencing.

Kijas JM, Juneja RK, Gäfvert S, Andersson L.

Anim Genet. 2000 Oct;31(5):326-8.

PMID:
11105214
19.

Foamy virus vectors come of age.

Williams DA.

Mol Ther. 2008 Apr;16(4):635-6. doi: 10.1038/mt.2008.34. No abstract available.

20.

Lentiviral vectors for enhanced gene expression in human hematopoietic cells.

Ramezani A, Hawley TS, Hawley RG.

Mol Ther. 2000 Nov;2(5):458-69.

Supplemental Content

Support Center